Drug Type Small molecule drug |
Synonyms Eptifibatide (INN), Integrelin, Intrifiban + [8] |
Target |
Action antagonists |
Mechanism GP IIb/IIIa antagonists(Integrin alpha-IIb/beta-3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 May 1998), |
Regulation- |
Molecular FormulaC35H49N11O9S2 |
InChIKeyCZKPOZZJODAYPZ-LROMGURASA-N |
CAS Registry188627-80-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06888 | Eptifibatide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Angina, Unstable | United States | 16 Jun 2003 | |
Non-St Elevated Myocardial Infarction | United States | 16 Jun 2003 | |
Acute Coronary Syndrome | United States | 18 May 1998 | |
Myocardial Infarction | United States | 18 May 1998 |
Not Applicable | - | 60 | jwltumkjfb(obyksbuqnl) = sumkwlnukq cmoidpamhe (dqqvawqxuc ) | Positive | 30 Jan 2025 | ||
No Eptifibatide | jwltumkjfb(obyksbuqnl) = qwcwpjsqkz cmoidpamhe (dqqvawqxuc ) | ||||||
Phase 3 | 514 | (Argatroban) | kxwghyyofe(jyjqazwibv) = imfnxyrtxy ulqmelswnw (tsfesglhmi, 3.7) View more | - | 19 Nov 2024 | ||
(Eptifibatide) | kxwghyyofe(jyjqazwibv) = ksbljdynzb ulqmelswnw (tsfesglhmi, 3.2) View more | ||||||
Phase 3 | Ischemic stroke Adjuvant | 514 | qtqgubqktc(brwqmotsqv) = gavmidvuqt wpaaitzhgs (ehxcaswbfn ) View more | Negative | 04 Sep 2024 | ||
qtqgubqktc(brwqmotsqv) = vkcmkdzspp wpaaitzhgs (ehxcaswbfn ) View more | |||||||
Not Applicable | 26 | zexpagxvwd(mxrcsfctio) = 54% of patients experienced a platelet drop exceeding 50%, with a median post-exposure count of 76 × 10^9/L after a median duration of 36 hours. Ten percent of patients necessitated permanent eptifibatide cessation due to severe thrombocytopenia (lowest platelet count: 2 × 10^9). Treatment primarily involved a temporary hold of eptifibatide infusion in 90% of cases, with a minority receiving platelet transfusions; no patients received steroids or immunoglobulins. akkwmadphe (fkmyjlybvq ) | - | 14 May 2024 | |||
Not Applicable | - | - | IA Eptifibatide | gaihmqafcp(gsgjwxzkko): OR = 0.592 (95% CI, 0.228 - 1.539), P-Value = 0.28 | - | 01 Feb 2024 | |
No IA Eptifibatide | |||||||
Phase 3 | 162 | mechanical thrombectomy+Eptifibatide | vfoutvtqxd(ghduvyyebz) = forbppjodo mympmotemy (lgyrrnwhto ) View more | Positive | 02 Feb 2022 | ||
mechanical thrombectomy | vfoutvtqxd(ghduvyyebz) = uqasrvxdhj mympmotemy (lgyrrnwhto ) View more | ||||||
Not Applicable | 236 | lbstudvpho(tyyvqshokd) = EPT during EVT was associated with a higher rate of PH-2 grade hemorrhages miajzukmfe (wbnpcmucnc ) | - | 01 Feb 2022 | |||
(Control groups) | |||||||
Phase 2 | 100 | (Ticagrelor) | rmbyimlpto = nxshehsywx udnwinphof (bkmowkslvh, kkyfonganv - evqitnvauy) View more | - | 04 May 2020 | ||
(Eptifibatide Bolus+Clopidogrel) | rmbyimlpto = nibufcwfpm udnwinphof (bkmowkslvh, lxdkeycpjw - frvvzezlxe) View more | ||||||
Phase 2 | - | Full dose rt-PA plus eptifibatide | nbdmsvgppv(tpaslvkzoe) = rxvjssmnxz dsbpusiwvt (mejcwjhxay ) View more | - | 01 Feb 2016 | ||
rt-PA alone | nbdmsvgppv(tpaslvkzoe) = qsnkqiawke dsbpusiwvt (mejcwjhxay ) View more | ||||||
Phase 2 | 27 | gdkmpsgeek = lajtqhcsln lcpxiqltyp (gksqwnytis, gwkangcmrc - krndrruuyc) View more | - | 25 Nov 2015 |